See more : Kansai Nerolac Paints Limited (KANSAINER.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Advagene Biopharma Co., Ltd. (6709.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Advagene Biopharma Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Pharmarise Holdings Corporation (2796.T) Income Statement Analysis – Financial Results
- PT Rohartindo Nusantara Luas Tbk (TOOL.JK) Income Statement Analysis – Financial Results
- Softstar Entertainment Inc. (6111.TWO) Income Statement Analysis – Financial Results
- China TianYF Holdings Group Limited (8196.HK) Income Statement Analysis – Financial Results
- The Akita Bank, Ltd. (8343.T) Income Statement Analysis – Financial Results
Advagene Biopharma Co., Ltd. (6709.TWO)
About Advagene Biopharma Co., Ltd.
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. Its products in development include nasal spray influenza vaccine, allergy vaccines, and COVID-19 immunotherapy. The company is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 12.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -12.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 73.22M | 100.04M | 72.68M | 55.33M | 70.73M |
| General & Administrative | 20.12M | 19.77M | 21.75M | 20.46M | 28.12M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.12M | 19.77M | 21.75M | 20.46M | 28.12M |
| Other Expenses | 0.00 | 202.00K | 340.00K | 4.04M | 0.00 |
| Operating Expenses | 93.34M | 119.81M | 94.43M | 75.79M | 93.45M |
| Cost & Expenses | 93.34M | 119.81M | 94.43M | 75.79M | 93.45M |
| Interest Income | 1.02M | 1.31M | 1.53M | 1.70M | 0.00 |
| Interest Expense | 36.00K | 81.00K | 127.00K | 107.00K | 0.00 |
| Depreciation & Amortization | 12.00M | 11.60M | 7.73M | 7.89M | 4.56M |
| EBITDA | -80.07M | -106.69M | -84.83M | -62.17M | -94.29M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -93.34M | -118.30M | -92.56M | -70.06M | -98.84M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.23M | 1.43M | 1.74M | 5.63M | 7.23M |
| Income Before Tax | -92.11M | -118.38M | -92.69M | -70.16M | -91.62M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -92.11M | -118.38M | -92.69M | -70.16M | -91.62M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.83 | -2.40 | -1.88 | -1.57 | -2.05 |
| EPS Diluted | -1.83 | -2.40 | -1.88 | -1.57 | -2.05 |
| Weighted Avg Shares Out | 50.39M | 49.32M | 49.18M | 44.73M | 44.60M |
| Weighted Avg Shares Out (Dil) | 50.39M | 49.32M | 49.18M | 44.73M | 44.60M |
Source: https://incomestatements.info
Category: Stock Reports